Information generated by screening tools, readily available therapies and potential pathways to drug development are the cornerstone of informed clinical research and clinical trial design. In a new review in the August 2017 issue of SLAS DISCOVERY (formerly the Journal of Biomolecular Screening), authors Eric Chevet, Ph.D., of Inserm U1242 (Rennes, France) et al. analyze the recent literature and review the impact of unfolded protein response (UPR) in health and disease.